XBiotech is a biopharmaceutical company that discovers and develops True Human™ monoclonal antibodies derived from naturally immune human donors rather than animal immunization, offering a platform designed to produce safer and more effective therapeutic candidates. The company operates an integrated research and manufacturing facility in Austin, Texas, with a clinical pipeline focused on oncology, rheumatology, and neurology applications centered on anti-interleukin-1 alpha (IL-1a) antibodies, as well as infectious disease candidates targeting conditions such as MRSA, shingles, and influenza. XBiotech generates revenue through contract research and manufacturing services, leveraging its proprietary True Human™ platform and manufacturing infrastructure to advance its owned therapeutic programs and support partner collaborations.